Cancer systems immunology is a highly interdisciplinary field that is advancing our ability to understand and predict the complex behavior that orchestrates the interplay between tumors and the immune system.
Pre-existing enhancers interpret T cell signaling strength in an analogue manner to direct quantitative changes in gene expression within the context of an overall digital response.
Experiment-driven quantitative model of IL-2 secretion demonstrates how T cells integrate their digital antigen responses into an analog-scaled output.
A comprehensive literature review delineates the current knowledge of how systemic context, such as age and obesity, can impact CD8+ T cell function, anti-tumor immunity, and immunotherapy responsiveness.
HIV-specific T cells remain detectable for years in HIV-infected individuals on antiretroviral therapy and importantly, mostly (68%) recognize HIV viruses that have the capacity to rebound following treatment interruption.
A library of the paired peptide/HLA multimers and artificial APCs allows for construction of a large database of class I-restricted peptides and cognate tumor-reactive TCR genes at an unprecedented scale.
Tregs form an "immunosuppressive ring" around solid tumors that is broken down during adoptive cell therapy and cyclophosphamide combination immunotherapy.
A new, high-throughput in vivo MHC-I peptide minigene library platform shows that the naive immune system cannot eliminate cells presenting immunogenic antigens found at low frequencies within a growing tumor.
